

Mohammad Y Zaidi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4428874/publications.pdf>

Version: 2024-02-01

36
papers

606
citations

516710

16
h-index

642732

23
g-index

36
all docs

36
docs citations

36
times ranked

895
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 414-424.	1.7	3
2	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 150-160.	4.1	30
3	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. <i>Surgical Oncology</i> , 2021, 37, 101492.	1.6	15
4	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2908-2919.	1.7	4
5	STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1138-1148.	1.7	5
6	Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 134-146.	1.5	14
7	Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 155-164.	1.7	27
8	The Path to Whipple Reconstruction for Pancreatic Adenocarcinoma: Trans-Mesocolon or Through Ligament of Treitz?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2046-2053.	1.7	0
9	Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 156-164.	1.5	13
10	Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. <i>Annals of Surgical Oncology</i> , 2020, 27, 783-792.	1.5	20
11	Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 165-176.	1.7	26
12	Lending a hand for laparoscopic distal pancreatectomy: the optimal approach?. <i>Hpb</i> , 2020, 22, 690-701.	0.3	2
13	CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 4996-5004.	1.5	8
14	Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 4980-4995.	1.5	15
15	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. <i>British Journal of Cancer</i> , 2020, 123, 1377-1386.	6.4	4
16	The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. <i>International Journal of Hyperthermia</i> , 2020, 37, 1182-1188.	2.5	5
17	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. <i>Surgical Oncology</i> , 2020, 34, 292-297.	1.6	2
18	The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. <i>Annals of Surgical Oncology</i> , 2020, 27, 4894-4907.	1.5	11

#	ARTICLE	IF	CITATIONS
19	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. <i>Journal of Surgical Oncology</i> , 2020, 122, 980-985.	1.7	10
20	What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. <i>Clinical Colorectal Cancer</i> , 2020, 19, e1-e7.	2.3	14
21	Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 756-767.	2.0	21
22	Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment?. <i>Journal of Surgical Oncology</i> , 2019, 120, 611-623.	1.7	21
23	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. <i>Annals of Surgical Oncology</i> , 2019, 26, 3542-3549.	1.5	19
24	Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?. <i>Journal of Surgical Oncology</i> , 2019, 120, 1293-1301.	1.7	19
25	A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique. <i>Journal of Surgical Oncology</i> , 2019, 120, 932-939.	1.7	11
26	The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multi-institutional propensity score analysis from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2019, 120, 332-339.	1.7	25
27	The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. <i>Surgery</i> , 2019, 166, 15-21.	1.9	34
28	Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. <i>Annals of Surgical Oncology</i> , 2019, 26, 2517-2524.	1.5	38
29	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 2234-2240.	1.5	16
30	Caution: Increased Acute Kidney Injury in Enhanced Recovery after Surgery (ERAS) Protocols. <i>American Surgeon</i> , 2019, 85, 156-161.	0.8	21
31	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, 270, 422-433.	4.2	53
32	Identifying the barriers to gastric cancer care at safety-net hospitals: A novel comparison of a safety-net hospital to a neighboring quaternary referral academic center in the same healthcare system. <i>Journal of Surgical Oncology</i> , 2019, 119, 64-70.	1.7	9
33	The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8-institution study from the US Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2019, 119, 5-11.	1.7	5
34	Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. <i>JAMA Surgery</i> , 2019, 154, 134.	4.3	54
35	Evaluation and management of incidental gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 37-37.	1.2	13
36	Postoperative surveillance in retroperitoneal soft tissue sarcoma: The importance of tumor histology in guiding strategy. <i>Journal of Surgical Oncology</i> , 2018, 117, 99-104.	1.7	19